273 related articles for article (PubMed ID: 24584107)
21. Cobicistat + elvitegravir + emtricitabine + tenofovir. Two new drugs, but no progress.
Prescrire Int; 2013 Oct; 22(142):233-5. PubMed ID: 24298581
[TBL] [Abstract][Full Text] [Related]
22. Boosting HIV treatment options: good news, new challenges.
Cahn P; Sued O
J Infect Dis; 2013 Jul; 208(1):4-6. PubMed ID: 23532095
[No Abstract] [Full Text] [Related]
23. Stribild: a review of component characteristics and combination drug efficacy.
Murrell DE; Moorman JP; Harirforoosh S
Eur Rev Med Pharmacol Sci; 2015; 19(5):904-14. PubMed ID: 25807445
[TBL] [Abstract][Full Text] [Related]
24. Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment.
Post FA; Winston J; Andrade-Villanueva JF; Fisher M; Liu Y; Beraud C; Abram ME; Graham H; Rhee MS; Cheng AK; Szwarcberg J;
J Acquir Immune Defic Syndr; 2015 Mar; 68(3):310-3. PubMed ID: 25469527
[TBL] [Abstract][Full Text] [Related]
25. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Greig SL; Deeks ED
Drugs; 2016 Jun; 76(9):957-68. PubMed ID: 27189707
[TBL] [Abstract][Full Text] [Related]
26. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
[TBL] [Abstract][Full Text] [Related]
27. The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet.
Marchand C
Expert Opin Investig Drugs; 2012 Jul; 21(7):901-4. PubMed ID: 22571404
[TBL] [Abstract][Full Text] [Related]
28. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.
Maggiolo F; Rizzardini G; Raffi F; Pulido F; Mateo-Garcia MG; Molina JM; Ong E; Shao Y; Piontkowsky D; Das M; McNicholl I; Haubrich R
Lancet HIV; 2019 Oct; 6(10):e655-e666. PubMed ID: 31578954
[TBL] [Abstract][Full Text] [Related]
29. Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results.
Gallant JE; Koenig E; Andrade-Villanueva JF; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Rizzardini G; Fehr J; Liu HC; Abram ME; Cao H; Szwarcberg J
J Acquir Immune Defic Syndr; 2015 Jul; 69(3):338-40. PubMed ID: 26181707
[TBL] [Abstract][Full Text] [Related]
30. Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
Inciarte A; Leal L; González E; León A; Lucero C; Mallolas J; Torres B; Laguno M; Rojas J; Martínez-Rebollar M; González-Cordón A; Cruceta A; Arnaiz JA; Gatell JM; García F;
J Antimicrob Chemother; 2017 Oct; 72(10):2857-2861. PubMed ID: 29091217
[TBL] [Abstract][Full Text] [Related]
31. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection.
Lyseng-Williamson KA; Scott LJ
Clin Drug Investig; 2012 Oct; 32(10):715-22. PubMed ID: 22921088
[TBL] [Abstract][Full Text] [Related]
32. Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF.
Mills A; Garner W; Pozniak A; Berenguer J; Speck RM; Bender R; Nguyen T
Patient; 2015 Aug; 8(4):359-71. PubMed ID: 26045359
[TBL] [Abstract][Full Text] [Related]
33. Drug updates and approvals: 2012 in review.
Belavic JM
Nurse Pract; 2013 Feb; 38(2):24-42; quiz 42-3. PubMed ID: 23295643
[TBL] [Abstract][Full Text] [Related]
34. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection.
Deeks ED; Perry CM
Drugs; 2010 Dec; 70(17):2315-38. PubMed ID: 21080746
[TBL] [Abstract][Full Text] [Related]
35. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a review of its use in HIV infection.
Deeks ED
Drugs; 2014 Nov; 74(17):2079-95. PubMed ID: 25352394
[TBL] [Abstract][Full Text] [Related]
36. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
Antivir Ther; 2017; 22(5):443-446. PubMed ID: 28076335
[TBL] [Abstract][Full Text] [Related]
37. A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
Angione SA; Cherian SM; Özdener AE
J Pharm Pract; 2018 Apr; 31(2):216-221. PubMed ID: 28558493
[TBL] [Abstract][Full Text] [Related]
38. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.
Squires K; Kityo C; Hodder S; Johnson M; Voronin E; Hagins D; Avihingsanon A; Koenig E; Jiang S; White K; Cheng A; Szwarcberg J; Cao H
Lancet HIV; 2016 Sep; 3(9):e410-e420. PubMed ID: 27562742
[TBL] [Abstract][Full Text] [Related]
39. Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF.
Gathe J; Arribas JR; Van Lunzen J; Garner W; Speck RM; Bender R; Shreay S; Nguyen T
Patient; 2015 Oct; 8(5):445-54. PubMed ID: 26286337
[TBL] [Abstract][Full Text] [Related]
40. Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection.
Perry CM
Drugs; 2009; 69(7):843-57. PubMed ID: 19441871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]